FDA Approves New Tricuspid Valve Repair System

The device offers a new, minimally invasive option for patients in the U.S. with severe tricuspid regurgitation.

Updated on Oct. 21, 2026 in Heart Disease

FDA Approves New Tricuspid Valve Repair System

Live Poll

Do you believe new medical technology typically leads to better health outcomes for patients?

The FDA has granted approval to the Edwards Lifesciences Pascal Precision system for the treatment of severe tricuspid regurgitation. This transcatheter technology offers a new option for patients in the U.S. seeking minimally invasive repair of heart valves.

Why it matters

This approval provides a new approach for managing tricuspid regurgitation, a condition where the valve does not close properly. It expands the available transcatheter repair options for patients by using an implantable device to improve valve function.

This FDA approval follows the manufacturer's regulatory filing for the Pascal Precision system. Clinical data from the pivotal trial, which evaluates the safety and efficacy of the device, are currently pending and not yet publicly released.

The players

Edwards Lifesciences

A medical technology company specializing in structural heart disease therapies, including transcatheter valve repair and replacement systems.

FDA

The federal agency responsible for evaluating the safety and efficacy of medical devices before they enter the U.S. market.

The details

The Pascal Precision system works through a transcatheter edge-to-edge repair technique delivered via the femoral artery. The device is designed to independently grasp the leaflets of the tricuspid valve, allowing surgeons to reposition the implant before achieving final closure. By securing the leaflets together, the system aims to create a tighter seal to reduce regurgitation.

2022: Pascal Precision received FDA approval for mitral regurgitation.
October 31 to November 3, 2026: Clinical data from the pivotal trial will be presented at the TCT conference.

Health Landscape

This approval expands the current standard of care by making Edwards Lifesciences the only provider of both mitral and tricuspid transcatheter repair and replacement therapies in the U.S. It reflects the ongoing transition toward minimally invasive structural heart interventions.

This device represents a new potential treatment for patients diagnosed with severe tricuspid regurgitation. If you are currently managing a heart valve condition, it is worth discussing with your cardiologist whether transcatheter repair options are appropriate for your specific case.

The takeaway

The Pascal Precision system offers a new transcatheter path for repairing heart valves without traditional open surgery. Patients should consult their physician to understand if this new technology fits into their long-term heart health plan.

What happens next

Clinical data from the Pascal Precision pivotal trial will be presented at the Transcatheter Cardiovascular Therapeutics conference in San Diego from October 31 to November 3, 2026.